Quantitative analysis of HDAC inhibition using the TGx-HDACi transcriptomic biomarker in human TK6 cells

Transcriptomic biomarkers provide an objective approach for extracting mechanistic information from complex gene expression datasets and may support quantitative applications in chemical assessment. TGx-HDACi is an 81-gene transcriptomic biomarker designed to identify histone deacetylase inhibitors (HDACi) in human TK6 cells. We evaluated whether benchmark concentrations (BMCs) derived from TGx-HDACi responses are concordant with BMCs based on reductions in HDAC enzyme activity. Human TK6 cells were exposed to concentration ranges of three HDAC inhibitors from different representative classes: the pan-HDAC inhibitors trichostatin A (TSA) and valproic acid (VPA), and the class I-selective inhibitor entinostat. HDAC enzyme activity and TGx-HDACi responses were assessed, and concentration-response modeling was performed to derive BMCs. TGx-HDACi correctly identified all three compounds as HDAC inhibitors and showed concentration-dependent responses. For TSA and VPA, TGx-HDACi and HDAC activity BMCs had overlapping confidence intervals, indicating good agreement between potency measures. In contrast, entinostat produced higher TGx-HDACi BMCs than the enzyme assay. This reduced quantitative concordance may reflect differences in HDAC selectivity, as TGx-HDACi was developed primarily using pan-HDAC inhibitors and appears less responsive to the more limited transcriptional changes induced by class I-selective inhibitors. Overall, these results demonstrate that TGx-HDACi reliably identifies HDAC inhibition and can provide potency estimates that align with enzyme activity measures for some HDAC inhibitor classes. However, the findings highlight the importance of considering biomarker applicability domain when interpreting potency estimates across compounds with differing HDAC selectivity.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-16
DOI
https://doi.org/10.64898/2026.11.13.766538
Primary Topic
Histone Deacetylase Inhibitors Research
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Quantitative analysis of HDAC inhibition using the TGx-HDACi transcriptomic biomarker in human TK6 cells

Andrew Williams, Eunnara Cho, Carole Lyn Yauk
bioRxiv (Cold Spring Harbor Laboratory)
Histone Deacetylase Inhibitors Research
preprint

Quantitative analysis of HDAC inhibition using the TGx-HDACi transcriptomic biomarker in human TK6 cells

Andrew Williams, Eunnara Cho, Carole Lyn Yauk
preprint en

Abstract

Transcriptomic biomarkers provide an objective approach for extracting mechanistic information from complex gene expression datasets and may support quantitative applications in chemical assessment. TGx-HDACi is an 81-gene transcriptomic biomarker designed to identify histone deacetylase inhibitors (HDACi) in human TK6 cells. We evaluated whether benchmark concentrations (BMCs) derived from TGx-HDACi responses are concordant with BMCs based on reductions in HDAC enzyme activity. Human TK6 cells were exposed to concentration ranges of three HDAC inhibitors from different representative classes: the pan-HDAC inhibitors trichostatin A (TSA) and valproic acid (VPA), and the class I-selective inhibitor entinostat. HDAC enzyme activity and TGx-HDACi responses were assessed, and concentration-response modeling was performed to derive BMCs. TGx-HDACi correctly identified all three compounds as HDAC inhibitors and showed concentration-dependent responses. For TSA and VPA, TGx-HDACi and HDAC activity BMCs had overlapping confidence intervals, indicating good agreement between potency measures. In contrast, entinostat produced higher TGx-HDACi BMCs than the enzyme assay. This reduced quantitative concordance may reflect differences in HDAC selectivity, as TGx-HDACi was developed primarily using pan-HDAC inhibitors and appears less responsive to the more limited transcriptional changes induced by class I-selective inhibitors. Overall, these results demonstrate that TGx-HDACi reliably identifies HDAC inhibition and can provide potency estimates that align with enzyme activity measures for some HDAC inhibitor classes. However, the findings highlight the importance of considering biomarker applicability domain when interpreting potency estimates across compounds with differing HDAC selectivity.

bioRxiv (Cold Spring Harbor Laboratory)
Health Canada (CA), University of Ottawa (CA)
Canada Research Chairs, Health Canada, Natural Sciences and Engineering Research Council of Canada
Good health and well-being
Histone Deacetylase Inhibitors Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon